Pursuant to regulation 30 of SEBI (LODR) Regulation, 2015, Intimation for the commencement of commercial Production for the new and existing Production Unit.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.9 pts more than Nifty Microcap 250 and 9.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Syschem India has started commercial production at two units at its Panchkula, Haryana facility from 5th January 2026. The new 'Ganga' unit will manufacture Cloxacillin Sodium, Dicloxacillin Sodium and Flucloxacillin Sodium with an installed capacity of 600 MT per annum. The expanded 'SARU' unit will manufacture Amoxicillin with an additional installed capacity of 1,200 MT per annum. The company says this follows the board approval from September 2025 and there is no material deviation from the original plan. Together, the new and expanded units add 1,800 MT of annual manufacturing capacity, which the company expects to enhance overall production capacity, improve operational efficiency, and meet growing market demand.
This is a positive operational milestone that expands the company's manufacturing capacity and could support future revenue growth, though it remains to be seen how quickly the new capacity is utilised and monetised.